New Retina Radio
Episode 35

Faricimab in Phase 2 and 3

Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE.

6/29/2020 | 9:47

More Episodes: